PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-11-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2011-03-344374PMID 21937691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues

  2011cited by this paper
• Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

  2011cited by this paper
• Primary mediastinal (thymic) large B-cell lymphoma

  2011cited by this paper
• Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma.

  2011cited by this paper
• The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

  2011cited by this paper
• A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

  2010cited by this paper
• Aggressive lymphomas.

  2010cited by this paper
• PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

  2010cited by this paper
• Pim kinase inhibitors: a survey of the patent literature

  2010cited by this paper
• Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

  2010cited by this paper
• Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.

  2009cited by this paper
• Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.

  2009cited by this paper
• A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

  2009cited by this paper
• Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

  2009cited by this paper
• Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells

  2009cited by this paper
• PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

  2009cited by this paper
• Functional signatures identified in B-cell non-Hodgkin lymphoma profiles

  2009cited by this paper
• Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.

  2008cited by this paper
• Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

  2008cited by this paper
• Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

  2008cited by this paper
• Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma

  2008cited by this paper
• Elevated Levels of Oncogenic Protein Kinase Pim-1 Induce the p53 Pathway in Cultured Cells and Correlate with Increased Mdm2 in Mantle Cell Lymphoma*

  2008cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Abstract 1523: Pim-1 Regulates Cardiomyocyte Survival Downstream of Akt

  2006cited by this paper
• The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C.

  2006cited by this paper
• Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma.

  2006cited by this paper
• The serine/threonine kinase Pim-1.

  2005cited by this paper
• State-of-the-art therapeutics: diffuse large B-cell lymphoma.

  2005cited by this paper
• The survival kinases Akt and Pim as potential pharmacological targets.

  2005cited by this paper
• Structure and Substrate Specificity of the Pim-1 Kinase*

  2005cited by this paper
• Pim Family Kinases Enhance Tumor Growth of Prostate Cancer Cells

  2005cited by this paper
• Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.

  2004cited by this paper
• Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors

  2004cited by this paper
• Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma

  2004cited by this paper
• The Oncogenic Serine/Threonine Kinase Pim-1 Phosphorylates and Inhibits the Activity of Cdc25C-associated Kinase 1 (C-TAK1)

  2004cited by this paper
• Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site

  2004cited by this paper
• Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation

  2004cited by this paper
• The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.

  2003cited by this paper
• The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death*

  2003cited by this paper
• Prolactin-regulated pim-1 transcription

  2003cited by this paper
• High-throughput retroviral tagging to identify components of specific signaling pathways in cancer

  2002cited by this paper
• A molecular compendium of genes expressed in multiple myeloma.

  2002cited by this paper
• Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.

  2002cited by this paper
• Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

  2001cited by this paper
• Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.

  1999cited by this paper
• Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2.

  1995cited by this paper
• Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

  1989cited by this paper
• The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias.

  1989cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Targeting Pim2 Improves Antitumor Immunity through Promoting Effector Function and Persistence of CD8 T cells.

  2026cites this paper
• Neuro-related gene signatures predict prognosis in diffuse large B-Cell lymphoma and uncover TRPV2-mediated tumor microenvironment regulation

  2026cites this paper
• Prognostic significance and pathogenesis of RFC3 gene expression in diffuse large B-cell lymphoma

  2025cites this paper
• Prognostic marker Musashi-2 modulates DNA damage response and radioresistance in diffuse large B-cell lymphoma

  2025cites this paper
• Differential expression of proliferation and immune response genes between children and adults influences survival of diffuse large B cell lymphoma

  2025cites this paper
• Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma

  2025cites this paper
• Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype

  2025influential citation
• Identification of RFC5 as a potential prognostic biomarker in diffuse large B-cell lymphoma: a combined bioinformatics and immunohistochemical study

  2025cites this paper
• Overlapping Gene Expression and Molecular Features in High-Grade B-Cell Lymphoma

  2024cites this paper
• Unveiling CKS2 : A Key Player in Aggressive B‐Cell Lymphoma Progression and a Target for Synergistic Therapy

  2024cites this paper
• Identification of oxidative stress-related hub genes for predicting prognosis in diffuse large B-cell lymphoma.

  2024cites this paper
• HIF-1 activated by PIM1 assembles a pathological transcription complex and regulon that drives JAK2V617F MPN disease

  2024cites this paper
• An XBP1s–PIM-2 positive feedback loop controls IL-15–mediated survival of natural killer cells

  2023cites this paper
• Virtual tissue expression analysis

  2023cites this paper
• Bifunctional inhibitor reveals NEK2 as a therapeutic target and regulator of oncogenic pathways in lymphoma.

  2023cites this paper
• Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma

  2023cites this paper
• Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

  2023cites this paper
• Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma

  2023cites this paper
• Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma

  2023cites this paper
• Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma

  2023cites this paper
• Targeting Pim kinases in hematological cancers: molecular and clinical review

  2023cites this paper
• Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

  2022cites this paper
• Bioinformatics Analysis of miRNAs Targeting TRAF5 in DLBCL Involving in NF-κB Signaling Pathway and Affecting the Apoptosis and Signal Transduction

  2022cites this paper
• Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma

  2022cites this paper
• Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.

  2022cites this paper
• Richter Syndrome: From Molecular Pathogenesis to Druggable Targets

  2022cites this paper
• Identification of Hub Genes and Key Pathways Associated with Follicular Lymphoma

  2022influential citation
• Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma

  2022cites this paper
• High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients

  2022cites this paper
• HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia

  2021cites this paper
• Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase

  2021cites this paper
• Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies

  2021cites this paper
• The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

  2021cites this paper
• Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers

  2021influential citation
• Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma

  2021cites this paper
• PIM2 and NF-κβ gene expression in a sample of AML and ALL Egyptian patients and its relevance to response to treatment

  2021cites this paper
• Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer

  2021cites this paper
• Mantle cell lymphoma: insights into therapeutic targets at the preclinical level

  2020cites this paper
• Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to graft-versus-leukemia

  2020cites this paper
• Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation

  2020cites this paper
• PIM2 deletion alleviates lipopolysaccharide (LPS)-induced respiratory distress syndrome (ARDS) by suppressing NLRP3 inflammasome.

  2020cites this paper
• Biosystem Analysis of the Hypoxia Inducible Domain Family Member 2A: Implications in Cancer Biology

  2020influential citation
• HDAC3 functions as a positive regulator in Notch signal transduction

  2020cites this paper
• MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma

  2020cites this paper
• Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect

  2020cites this paper
• OTT_A_253758 10475..10487

  2020cites this paper
• Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.

  2019cites this paper
• AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK

  2019cites this paper
• PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism

  2019cites this paper
• PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells

  2019cites this paper
• Novel Therapies in Paediatric NHL

  2019cites this paper
• CD81 is a novel immunotherapeutic target for B cell lymphoma

  2019cites this paper
• Influence of the bispecific antibody IgG subclass on T cell redirection

  2019cites this paper
• TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells

  2019cites this paper
• Expression of the PIM 2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia

  2019cites this paper
• Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells.

  2019cites this paper
• Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

  2018cites this paper
• Proviral insertion in murine lymphomas 2 promotes stomach cancer progression by regulating apoptosis via reactive oxygen species-triggered endoplasmic reticulum stress.

  2018cites this paper
• Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma

  2018cites this paper
• PIM‐2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity

  2018cites this paper
• Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking

  2018influential citation
• Mechanisms of TRAF3 mediated regulation of B cell survival

  2018cites this paper
• Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway

  2018cites this paper
• The uses of cyclohexan-1,4-dione for the synthesis of thiophene derivatives as new anti-proliferative, prostate anticancer, c-Met and tyrosine kinase inhibitors

  2018cites this paper
• Discovery of new thiophene, pyrazole, isoxazole derivatives as antitumor, c-Met, tyrosine kinase and Pim-1 kinase inhibitors

  2018cites this paper
• Mutational profile of primary breast diffuse large B-cell lymphoma

  2017cites this paper
• Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center

  2017cites this paper
• The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

  2017cites this paper
• Exploring the nature of prediagnostic blood transcriptome markers of chronic lymphocytic leukemia by assessing their overlap with the transcriptome at the clinical stage

  2017cites this paper
• Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

  2016cites this paper
• The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

  2016cites this paper
• Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia

  2016cites this paper
• Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

  2016cites this paper
• Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists.

  2016cites this paper
• The role of PIM 1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma

  2016cites this paper
• Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas

  2015influential citation
• Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.

  2015cites this paper
• Multiple outcomes for PI3K/Akt/mTOR targeting in non-Hodgkin lymphoma

  2015cites this paper
• PIM Kinases in AML

  2015cites this paper
• Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation

  2015cites this paper
• Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185

  2015cites this paper
• Targeting the Pim kinases in multiple myeloma

  2015cites this paper
• A Regulatory Feedback Loop between HIF-1α and PIM2 in HepG2 Cells

  2014cites this paper
• Inhibidors de cinases com a estratègia terapèutica en neoplàsies limfoides

  2014cites this paper
• Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.

  2014cites this paper
• Pleiotropic antitumor effects of the pan‐HDAC inhibitor ITF2357 against c‐Myc‐overexpressing human B‐cell non‐Hodgkin lymphomas

  2014cites this paper
• A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas

  2014cites this paper
• The PIM Family of Serine/Threonine Kinases in Cancer

  2014cites this paper
• Pim kinases in hematological malignancies: where are we now and where are we going?

  2014cites this paper
• Molecular characterisation of paediatric ALL and new therapeutic strategies

  2014cites this paper
• Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

  2013cites this paper
• Aggressive B-cell lymphomas: how many categories do we need?

  2013cites this paper
• Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.

  2013cites this paper
• Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis

  2013cites this paper
• LATEXIN’S ROLE IN REGULATING HEMATOPOIETIC STEM AND PROGENITOR CELLS

  2013cites this paper
• Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma

  2013cites this paper
• Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.

  2013cites this paper
• PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION APPROACHES IN B-CELL LYMPHOMA

  2013cites this paper
• The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

  2013cites this paper
• Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

  2013cites this paper